Pharmaids Pharmaceuticals Share Price
Sector: Major Drugs
65.00 0.00 (0.00%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
63.10
Today’s High
67.00
52 Week Low
31.90
52 Week High
87.46
Key Metrics
- Market Cap (In Cr) 226.11
- Beta 0.55
- Div. Yield (%) 0
- P/B 3.18
- TTM P/E -
- Peg Ratio -
- Sector P/E 26.62
- Open Price 63.1
- Prev Close 65
Pharmaids Pharmaceuticals Analysis
Price Analysis
-
1 Week0.95%
-
3 Months-10.97%
-
6 Month101.86%
-
YTD-7.78%
-
1 Year8.73%
Risk Meter
- 62% Low risk
- 62% Moderate risk
- 62% Balanced Risk
- 62% High risk
- 62% Extreme risk
Pharmaids Pharmaceuticals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 15.11
- Selling/ General/ Admin Expenses Total
- 9.2
- Depreciation/ Amortization
- 1.72
- Other Operating Expenses Total
- 7.63
- Total Operating Expense
- 30.02
- Operating Income
- -14.91
- Net Income Before Taxes
- -15.62
- Net Income
- -7.97
- Diluted Normalized EPS
- -3.5
- Period
- 2024
- Total Assets
- 91.34
- Total Liabilities
- 19.29
- Total Equity
- 72.05
- Tangible Book Valueper Share Common Eq
- 11.37
- Period
- 2024
- Cashfrom Operating Activities
- -10.62
- Cashfrom Investing Activities
- -74.99
- Cashfrom Financing Activities
- 77.66
- Net Changein Cash
- -7.95
- Period
- 2023
- Total Revenue
- 0
- Selling/ General/ Admin Expenses Total
- 1.13
- Depreciation/ Amortization
- 0.02
- Other Operating Expenses Total
- 7.87
- Total Operating Expense
- 9.9
- Operating Income
- -9.9
- Net Income Before Taxes
- -9.91
- Net Income
- -7.56
- Diluted Normalized EPS
- -5.86
- Period
- 2023
- Total Assets
- 24.59
- Total Liabilities
- 2.13
- Total Equity
- 22.46
- Tangible Book Valueper Share Common Eq
- 10.45
- Period
- 2023
- Cashfrom Operating Activities
- -4.02
- Cashfrom Investing Activities
- -4.94
- Cashfrom Financing Activities
- 21.31
- Net Changein Cash
- 12.35
- Period
- 2022
- Total Revenue
- 3.94
- Selling/ General/ Admin Expenses Total
- 0.04
- Depreciation/ Amortization
- 0.01
- Other Operating Expenses Total
- 0.19
- Total Operating Expense
- 3.81
- Operating Income
- 0.13
- Net Income Before Taxes
- 0.14
- Net Income
- 0.15
- Diluted Normalized EPS
- 0.14
- Period
- 2022
- Total Assets
- 11.11
- Total Liabilities
- 2.44
- Total Equity
- 8.67
- Tangible Book Valueper Share Common Eq
- 8.41
- Period
- 2022
- Cashfrom Operating Activities
- -0.26
- Cashfrom Investing Activities
- 0.47
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- 0.21
- Period
- 2021
- Total Revenue
- 8.55
- Selling/ General/ Admin Expenses Total
- 0.04
- Depreciation/ Amortization
- 0.04
- Other Operating Expenses Total
- 0.24
- Total Operating Expense
- 8.49
- Operating Income
- 0.06
- Net Income Before Taxes
- 0.09
- Net Income
- 0.09
- Diluted Normalized EPS
- 0.09
- Period
- 2021
- Total Assets
- 9.12
- Total Liabilities
- 0.59
- Total Equity
- 8.53
- Tangible Book Valueper Share Common Eq
- 8.27
- Period
- 2021
- Cashfrom Operating Activities
- 0.41
- Cashfrom Investing Activities
- -0.23
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- 0.18
- Period
- 2020
- Total Revenue
- 0
- Selling/ General/ Admin Expenses Total
- 0.02
- Depreciation/ Amortization
- 0.04
- Other Operating Expenses Total
- 0.31
- Total Operating Expense
- 0.37
- Operating Income
- -0.37
- Net Income Before Taxes
- -0.38
- Net Income
- 0.03
- Diluted Normalized EPS
- 0.03
- Period
- 2020
- Total Assets
- 8.46
- Total Liabilities
- 0.03
- Total Equity
- 8.43
- Tangible Book Valueper Share Common Eq
- 8.18
- Period
- 2020
- Cashfrom Operating Activities
- -0.75
- Cashfrom Investing Activities
- 0.66
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- -0.09
- Period
- 2019
- Total Revenue
- 0.48
- Selling/ General/ Admin Expenses Total
- 0.03
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0.25
- Total Operating Expense
- 0.63
- Operating Income
- -0.15
- Net Income Before Taxes
- -0.15
- Net Income
- -0.18
- Diluted Normalized EPS
- -0.43
- Period
- 2019
- Total Assets
- 8.67
- Total Liabilities
- 0.27
- Total Equity
- 8.4
- Tangible Book Valueper Share Common Eq
- 8.15
- Period
- 2019
- Cashfrom Operating Activities
- -0.16
- Cashfrom Investing Activities
- 0.02
- Cashfrom Financing Activities
- -0.03
- Net Changein Cash
- -0.17
- Period
- 2018
- Total Revenue
- 0.45
- Selling/ General/ Admin Expenses Total
- 0.06
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0.28
- Total Operating Expense
- 0.84
- Operating Income
- -0.39
- Net Income Before Taxes
- -0.37
- Net Income
- -0.39
- Diluted Normalized EPS
- -1.13
- Period
- 2018
- Total Assets
- 1.3
- Total Liabilities
- 0.25
- Total Equity
- 1.04
- Tangible Book Valueper Share Common Eq
- 3.06
- Period
- 2018
- Cashfrom Operating Activities
- -0.21
- Cashfrom Investing Activities
- -0.09
- Cashfrom Financing Activities
- -0.07
- Net Changein Cash
- -0.37
- Period
- 2024-12-31
- Total Revenue
- 4.71
- Selling/ General/ Admin Expenses Total
- 3.25
- Depreciation/ Amortization
- 0.64
- Other Operating Expenses Total
- 1.35
- Total Operating Expense
- 8.24
- Operating Income
- -3.54
- Net Income Before Taxes
- -4.01
- Net Income
- -1.93
- Diluted Normalized EPS
- -0.55
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 5.24
- Selling/ General/ Admin Expenses Total
- 2.87
- Depreciation/ Amortization
- 0.61
- Other Operating Expenses Total
- 1.41
- Total Operating Expense
- 8.48
- Operating Income
- -3.24
- Net Income Before Taxes
- -3.56
- Net Income
- -2.22
- Diluted Normalized EPS
- -0.72
- Period
- 2024-09-30
- Total Assets
- 94.6
- Total Liabilities
- 27.45
- Total Equity
- 67.15
- Tangible Book Valueper Share Common Eq
- 9.98
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -1.43
- Cashfrom Investing Activities
- -2.46
- Cashfrom Financing Activities
- 1.88
- Net Changein Cash
- -2.01
- Period
- 2024-06-30
- Total Revenue
- 4.73
- Selling/ General/ Admin Expenses Total
- 2.99
- Depreciation/ Amortization
- 0.57
- Other Operating Expenses Total
- 1.37
- Total Operating Expense
- 8.78
- Operating Income
- -4.05
- Net Income Before Taxes
- -4.3
- Net Income
- -2.68
- Diluted Normalized EPS
- -0.75
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 15.09
- Selling/ General/ Admin Expenses Total
- 7.21
- Depreciation/ Amortization
- 1.69
- Other Operating Expenses Total
- 5.71
- Total Operating Expense
- 26.07
- Operating Income
- -10.97
- Net Income Before Taxes
- -10.92
- Net Income
- -4.53
- Diluted Normalized EPS
- -1.72
- Period
- 2024-03-31
- Total Assets
- 91.34
- Total Liabilities
- 19.29
- Total Equity
- 72.05
- Tangible Book Valueper Share Common Eq
- 11.37
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -10.62
- Cashfrom Investing Activities
- -74.99
- Cashfrom Financing Activities
- 77.66
- Net Changein Cash
- -7.95
- Period
- 2023-12-31
- Total Revenue
- 0.02
- Selling/ General/ Admin Expenses Total
- 0.49
- Depreciation/ Amortization
- 0.04
- Other Operating Expenses Total
- 1.95
- Total Operating Expense
- 2.5
- Operating Income
- -2.47
- Net Income Before Taxes
- -1.73
- Net Income
- -1.15
- Diluted Normalized EPS
- -0.54
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 0
- Selling/ General/ Admin Expenses Total
- 0.47
- Depreciation/ Amortization
- 0.01
- Other Operating Expenses Total
- 0.55
- Total Operating Expense
- 1.03
- Operating Income
- -1.03
- Net Income Before Taxes
- -1.29
- Net Income
- -0.5
- Diluted Normalized EPS
- -0.24
- Period
- 2023-09-30
- Total Assets
- 20.86
- Total Liabilities
- 0.24
- Total Equity
- 20.62
- Tangible Book Valueper Share Common Eq
- 9.6
- Period
- 2023-09-30
- Cashfrom Operating Activities
- -0.37
- Cashfrom Investing Activities
- -11.45
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- -11.82
- Period
- 2023-06-30
- Total Revenue
- 0
- Selling/ General/ Admin Expenses Total
- 0.36
- Depreciation/ Amortization
- 0.01
- Other Operating Expenses Total
- 1.25
- Total Operating Expense
- 1.62
- Operating Income
- -1.62
- Net Income Before Taxes
- -1.21
- Net Income
- -1.3
- Diluted Normalized EPS
- -0.61
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 0
- Selling/ General/ Admin Expenses Total
- 0.42
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 7.29
- Total Operating Expense
- 8.6
- Operating Income
- -8.6
- Net Income Before Taxes
- -8.6
- Net Income
- -6.16
- Diluted Normalized EPS
- -2.98
- Period
- 2023-03-31
- Total Assets
- 24.59
- Total Liabilities
- 2.13
- Total Equity
- 22.46
- Tangible Book Valueper Share Common Eq
- 10.45
- Period
- 2023-03-31
- Cashfrom Operating Activities
- -4.02
- Cashfrom Investing Activities
- -4.94
- Cashfrom Financing Activities
- 21.31
- Net Changein Cash
- 12.35
- Period
- 2022-12-31
- Total Revenue
- 0
- Selling/ General/ Admin Expenses Total
- 0.37
- Depreciation/ Amortization
- 0.01
- Other Operating Expenses Total
- 0.32
- Total Operating Expense
- 0.7
- Operating Income
- -0.7
- Net Income Before Taxes
- -0.7
- Net Income
- -0.71
- Diluted Normalized EPS
- -0.68
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Pharmaids Pharmaceuticals Technical
Moving Average
SMA
- 5 Day65.7
- 10 Day65.87
- 20 Day66.96
- 50 Day67.86
- 100 Day68.27
- 300 Day57.56
Pharmaids Pharmaceuticals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Brooks Laboratories
- 139
- -1
- -0.71
- 202.8
- 72.51
- 409.45
- Ambalal Sarabhai Enterprises
- 37.51
- -0.44
- -1.16
- 77.7
- 34.11
- 287.45
- Pharmaids Pharmaceuticals
- 65
- 0
- 0
- 87.46
- 31.9
- 226.11
- Bharat Immunologica And Bio Corp
- 23.13
- -0.29
- -1.24
- 35.88
- 19
- 99.88
- Welcure Drugs And Pharmaceutic
- 8.71
- 0.41
- 4.94
- 15.81
- 4.3
- 98
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Brooks Laboratories
- -
- 5.6
- -21.61
- -27.47
- Ambalal Sarabhai Enterprises
- 51.32
- 2.12
- 23.77
- 12.86
- Pharmaids Pharmaceuticals
- -
- 3.18
- -17.27
- -69.29
- Bharat Immunologica And Bio Corp
- -
- 1.15
- -23.67
- -16.7
- Welcure Drugs And Pharmaceutic
- -
- 8.37
- -6.66
- -49.3
Pharmaids Pharmaceuticals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 12-Feb-25
- Quarterly Results
- 13-Nov-24
- Quarterly Results
- 28-May-24
- Audited Results
- 12-Feb-24
- Quarterly Results
- 06-Jan-24
- Preferential issue of shares
- 11-Nov-23
- Quarterly Results
- 04-Aug-23
- Quarterly Results
- 29-May-23
- Audited Results
- 13-Feb-23
- Quarterly Results
- 17-Jan-23
- Others
- Meeting Date
- Announced on
- Purpose
- 26-Mar-25
- 19-Feb-25
- POM
- 25-Sept-24
- 30-Aug-24
- AGM
- 08-Jul-24
- 03-Jun-24
- POM
- 31-Jan-24
- 08-Jan-24
- EGM
- 22-Sept-23
- 12-Sept-23
- AGM
- 25-Sept-21
- 20-Aug-21
- AGM



